Many thanks Anuja Java, MD (she/her)! So glad you were there to help me out in the chat lol. Fun discussion for sure.

Our systematic review on rare variants and RA risk is out in NatRevRheumatol, led by Vanessa Kronzer, MD Huge opportunity to identify additional genetic variants that may lead to drug targets Soumya Raychaudhuri সৌম্য রায়চৌধুরী

nature.com/articles/s4158…

Alfred Kim This is using TriNetX so I would say purely hypothesis generating at the moment until replicated in other studies ideally as you said screening for the variants. Perhaps the UK biobank? Also which comes first, presumably the autoimmune disease.

Alfred Kim Agreed Alfred Kim — we should. And I speculate that it will be informative of more than macular degeneration.

This is interesting given that complement plays a major role in macular degeneration, which happens to overlap w/ a few of these autoimmune diseases. We don’t screen for GoF (FB, FD) nor LoF (FH, FI) variants in our pts w/ autoimmune dz. Maybe we should.

ncbi.nlm.nih.gov/pmc/articles/P…

Alfred Kim Looks like about a 0.6-1% risk of anaphylaxis with each Q3 month treatment- so a cumulative risk of 4% per year of anaphylaxis!

Ok, link to the Fact Sheet (invivyd.com/wp-content/upl…) in the press release. Eligible individuals pretty much same as Evusheld.

#rheum #rheum atology #rheum twitter #arthritis #curearthritis #spondy #spa Alfred Kim plague rat 🐀

Wow. In light of the recent news, I’m realizing that in retrospect this joke now feels insensitive.

I apologize to the Boeing Company for any harm I have caused ❤️

Alfred Kim This is very hard to prove. You would need evidence of a malignant, expanded T cell clone in the apheresed T cell pool already, prior to transduction and T cell expansion. If this was the case, autoimmune d. patients should be screened prior to CAR-T treatment going forward.

Interesting. Re: T cell lymphoma observed very rarely in CAR-T cell recipients:

Georg Schett heard from Carl June that the malignant T cell was likely present PRIOR to CAR-T cell admin. These malignant cells were transduced ex vivo & delivered back to the host.

#LUPUS2024

Congratulations to Christopher Egbulefu on his new preprint publication on Research Square: Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapse. assets.researchsquare.com/files/rs-39922……
UT Southwestern Biomedical Engineering

Colleagues Please Repost! This is a predatory journal that is calling itself 'Journal of Immunology' soliciting papers. The real deal is 'THE Journal of Immunology (AAI, J Immunol) . This is pretty insidious. Be aware....

#Match2024
If you need to #SOAP

My DMs are open for whatever materials I can review that are helpful

Please reach out and I’ll try my best the next couple of days to respond

For reference I did IM residency 2014-2017 and am currently IM subspecialty faculty in academics

I applaud Maisons et al., on this fantastic work on etiology & outcomes of RENAL LIMTED TMA (kidney-international.org/article/S0085-…). 45% of all TMA diagnoses in 757 pts. Can result from any cause of TMA including complement TMA/aHUS (43% renal limited). Bx is a must for diagnosis. #renalpath